PMA device
Inspire Programmer System
Inspire Medical Systems · Stimulator, Hypoglossal Nerve, Implanted, Apnea (MNQ, Class III) · First FDA decision Feb 12, 2021, newest Feb 12, 2021Sleep apnea
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "Inspire Programmer"
MAUDE reports
0
Brand "Inspire Programmer", since 2015
PubMed studies
0
Mentioning "Inspire Programmer"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Inspire Programmer System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Inspire Programmer SystemPMA supplement
P130008-S056 · Decided Feb 12, 2021 · 196 days after receipt · Normal 180 Day Track
Device type: Stimulator, hypoglossal nerve, implanted, apnea (MNQ) · Anesthesiology & Respiratory
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38387Wellpoint FederalUpdated Jul 14, 2026
- Hypoglossal Nerve Stimulation for Obstructive Sleep ApneaLocal determinationIn effectL38276Palmetto GBAUpdated May 8, 2026
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38528WPS Insurance CorporationUpdated Mar 20, 2026
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38307CGS Administrators, LLCUpdated Feb 27, 2026
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38310Noridian Healthcare Solutions, LLCUpdated Oct 16, 2025
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38398First Coast Service Options, Inc.Updated Jan 24, 2020
- Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaLocal determinationIn effectL38385Novitas Solutions, Inc.Updated Jan 24, 2020
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
Clinical trials
Device studies on ClinicalTrials.gov that name "Inspire Programmer", any status and sponsor, newest update first.
No registered device study names "Inspire Programmer".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Inspire Programmer", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MNQ
3,753 reports: 165 malfunction, 3,581 injury, 4 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2515-2026 · Started May 11, 2026 · Posted by FDA Jun 18, 2026
Reason given: Products are labeled with incorrect Use By Date, extending beyond the validated three-year shelf life from date of manufacturer. Material degradation of a product past its Use By Date may result in unplanned or premature revision surgery.
Cause as FDA categorized it: Process control · Device type: Stimulator, Hypoglossal Nerve, Implanted, Apnea (MNQ)
Z-2516-2026 · Started May 11, 2026 · Posted by FDA Jun 18, 2026
Reason given: Products are labeled with incorrect Use By Date, extending beyond the validated three-year shelf life from date of manufacturer. Material degradation of a product past its Use By Date may result in unplanned or premature revision surgery.
Cause as FDA categorized it: Process control · Device type: Stimulator, Hypoglossal Nerve, Implanted, Apnea (MNQ)
Z-2969-2018 · Started Jun 12, 2018
Reason given: Incorrect use-by date on the device registration/patient file labels.
Cause as FDA categorized it: Error in labeling · Device type: Stimulator, Hypoglossal Nerve, Implanted, Apnea (MNQ)
Published research
The most relevant PubMed records for "Inspire Programmer"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MNQ.
- Inspire II Upper Airway StimulatorInspire Medical Systems · PMA 2026
- Inspire® Upper Airway StimulationInspire Medical Systems · PMA 2025
- aura6000 systemLivaNova USA, Inc. · PMA 2026
- Genio® System 2.1Nyxoah S.A. · PMA 2025
- Inspire UAS High AHI/High BMIInspire Medical Systems · PMA 2023
- SleepSync ProgrammerInspire Medical Systems · PMA 2023
- Silicone Stimulation Lead, Silicone Sensing LeadInspire Medical Systems · PMA 2022
- Inspire Medical Systems, Model 2580 Patient ProgrammerInspire Medical Systems · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.